secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001790340-25-000077
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports interim Phase 2a data: 39% ORR, 81% DCR in first-line pancreatic cancer
--------------------------------------------------------------------------------

- As of May 26, 2025 cutoff: 1 CR, 13 PR (4 pending confirmation), 15 SD among 36 evaluable patients; DCR 81%, ORR 39%.
- In 320 mg ITT population (n=34): 94% OS and 72% PFS at 6 months median follow-up; median OS and PFS not reached.
- Grade≥3 TEAEs in ≥10% of 320 mg patients: anemia (18%) and neutropenia (15%); no Grade 5 events.
- Additional data expected Q4 2025; pivotal trial of atebimetinib+mGnP in 1L pancreatic cancer planned for 2026, pending regulatory feedback Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000077/0001790340-25-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000077/imrx-20250617.htm
  HTML page:      https://secwatch.observer/filing/0001790340-25-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer